NORTHLAND(BJ:430047)2024-02-25 16:00Financial Performance - The company expects a net loss attributable to shareholders of between -55 million to -43 million yuan for the fiscal year 2023, compared to a loss of 67.61 million yuan in the same period last year[3]. - The primary reason for the loss is that the company's biopharmaceutical new drug is still in the research and development stage and has not yet achieved market sales[4]. - The company incurred significant R&D expenses for the biopharmaceutical new drug, contributing to the continued loss during the reporting period[4]. Equity Incentive Plan - The company did not meet the third achievement condition of its equity incentive plan, leading to a reversal of previously accrued expenses related to the plan[5]. Performance Forecast - The performance forecast is based on preliminary calculations and has not been audited by an accounting firm, thus it does not constitute a performance commitment to investors[6].